	US 12,465,565 B2
	Pharmaceutical compositions of raltegravir
Vikram K. Karne, Pune (IN); Avinash K. Velhal, Pune (IN); Sanjay C. Wagh, Pune (IN); and Makarand K. Avachat, Pune (IN)
Assigned to Lupin Limited, Mumbai (IN)
Appl. No. 17/795,005
Filed by Lupin Limited, Mumbai (IN)
PCT Filed Jan. 22, 2021, PCT No. PCT/IB2021/050481 § 371(c)(1), (2) Date Jul. 25, 2022, PCT Pub. No. WO2021/148992, PCT Pub. Date Jul. 29, 2021.
Claims priority of application No. 202021003085 (IN), filed on Jan. 23, 2020.
Prior Publication US 2023/0073216 A1, Mar. 9, 2023
Int. Cl. A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/513 (2006.01)

CPC A61K 9/0053 (2013.01) [A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 31/513 (2013.01)]

4 Claims

1. A solid pharmaceutical composition for oral administration comprising:

(i) raltegravir or a pharmaceutically acceptable salt thereof,

(ii) acidifying agent selected from tartaric acid, citric acid and fumaric acid,

(iii) croscarmellose sodium,

(iv) povidone,

(v) microcrystalline cellulose, and

(vi) magnesium stearate.